Background and Objectives: In North America, preoperative combination chemor-
most commonly recommended practices have changed from postoperative combination chemoradiation to preoperative combination chemoradiation and adjuvant systemic chemotherapy.
Adherence to neoadjuvant chemoradiotherapy remains inadequate; however, with significant variation in treatment based on center type, volume, and geographic location. 3 More recently, single-center studies have reported the use of induction chemotherapy (IC) before combination chemotherapy and radiation followed by surgery, 4, 5 with the goals of introducing systemic therapy earlier in the course of treatment, and potentially increasing the rate of complete pathologic response. 6 Others have endorsed the delivery of all chemotherapy and radiation before surgery, recognizing that surgical complications preclude adjuvant chemotherapy in up to 34% of patients. 7, 8 There is only a small phase 2 randomized trial comparing IC to adjuvant chemotherapy, which did not identify a difference in pathologic complete response or survival between groups. 9 Despite this, the National Comprehensive Cancer Network Guidelines now include IC among endorsed options for treatment of stages 2 and 3 rectal cancer. 10 To date, large scale or randomized studies comparing IC against standard preoperative chemoradiation are lacking. The National
Cancer Institute-supported PROSPECT trial randomized patients to standard chemoradiation or IC with the selective omission of preoperative radiation, but outcomes of this trial are still forthcoming. 11 On the one hand, IC might induce the more preoperative response, reducing the likelihood of local failure, and treating occult metastatic disease earlier. On the other hand, delayed surgery might allow local expansion and worsen the likelihood of surgical margin clearance and leave more time for the primary tumor to metastasize.
The real-world outcomes of the IC strategy cannot be assessed without population-based evaluation outside of highly-selected case series. The prevalence of IC use outside of the highly specialized institutions that have reported its use is unknown.
In this study, we used the National Cancer Database (NCDB), which includes data from all American College of Surgeons Among patients who received radiation and/or chemotherapy as initial course of therapy, we defined two groups of interest using variables available in the NCDB (1) the IC group was defined as patients who received chemotherapy separate from radiation before surgery and (2) traditional therapy was defined as patients who received concurrent chemotherapy and radiation before surgery | 309 chemotherapy and radiation concurrently less than 10 days apart-in fact, a majority of these patients started both on the same day. To further specify the comparison group of traditional chemoradiotherapy followed by surgery, we excluded patients who underwent surgery greater than 22 weeks after chemotherapy and radiation, as these likely represent patients who initially refused surgery, had substantial complications of therapy, or initially pursued nonoperative management.
| Statistical analysis
Descriptive statistics were used to compare characteristics of patients between treatment groups, using χ 2 tests for categorical variables, the Student t test for continuous variables, and analysis of variance for multicategory comparisons of continuous data. We identified independent predictors of receiving IC using multivariable logistic regression, including patient factors (age, race, rectal cancer stage, place of residence, income, type of insurance, and receipt of postoperative chemotherapy) and hospital factors (regional location and facility type) that were significant in the univariate analysis. We categorized the hospital rate of IC into quartiles and included this in the model to account for the role of institutional practice patterns.
We compared overall survival between therapy regimens using multivariable Cox proportional hazard regression, adjusting for the same patient and hospital factors as above, and applying robust standard errors to account for clustering of outcomes within hospitals. All statistical analyses were conducted using STATA version 14 (StataCorp LP, College Station, TX).
3 | RESULTS
| Patient and hospital characteristics
Of 36 In multivariable logistic regression analysis, displayed in Table 3 
| Predictors of receipt of IC

| Clinical and pathologic outcomes, by treatment group
The proportion of patients who had complete tumor regression on pathology was not different between the IC and traditional groups (32.2% vs 30.4%, P = 0.20). Likewise, the unadjusted survival functions between the two treatment groups were not significantly different (P = 0.85). Graphical display of the Cox regression survival analysis, adjusting for patient and hospital factors, is shown in Figure 3 . Adjusting for patient and hospital characteristics, the IC group had equivalent survival to the traditional care group. Five-year survival for traditional therapy was 81.4%, while for IC, it was 82.4%, (P = 0.71).
| DISCUSSION
In this study, we find that, despite the lack of large randomized trials to support IC, there has been a steady annual increase in its use for clinical stages 2 and 3 rectal cancer and that the primary determinant of this use is institutional practice pattern, rather than clinical The use of IC is just one of several recent changes in the prevailing treatment approaches for rectal cancer. In general, the trend has been toward more treatment being given before surgery, with increasing interest in strategies that might obviate the need for surgery altogether for some patients. Improved surgical technique, with total mesorectal excision and negative circumferential margin, along with radiation, became the standard of care after studies showed a decreased risk of local recurrence. [13] [14] [15] [16] The German rectal cancer trial established that preoperative radiation was superior to postoperative treatment, less from improved survival than because of decreased toxicity. 2 Thus, some have pursued IC to avoid failures to receive chemotherapy after surgery due to perioperative complications. 8 In addition, Habr-Gama showed that preoperative multimodal treatment resulted in tumor shrinkage and thus improved sphincter preservation, suggesting a role for IC in reducing the rate of permanent colostomy. 17 In another study, some patients who achieved an apparent complete clinical response to preoperative therapy did well over time without surgery. 18 Since that time, multiple studies aimed to improve local tumor response through increasing multimodal preoperative therapy, though randomized, multi-institution data in support of such approaches is still lacking. East South Central by surgery and then chemotherapy to 308 patients receiving all of their therapy before surgery. 5 The only randomized trial was a phase 2 study from Spain which compared IC to adjuvant in a total of 108 patients and this study did not identify a difference in pathologic complete response (the primary endpoint) or survival between groups despite improved compliance with receipt of planned chemotherapy. 9, 21 In summary, the use of IC may achieve one of two goals. First, sensitive tumors will shrink completely before surgery and patients will receive earlier systemic therapy. The second is that many but not all patients receive a survival benefit from FOLFOX 22 and tumors with a greater period of time in situ will have a theoretical increased potential for metastasis before resection of the primary tumor. Two recent studies of rectal cancer patients with pathologic complete response using the NCDB found that these patients did have a survival benefit from adjuvant chemotherapy. 23, 24 However, we do not yet know how to predict who these patients are and these are clearly the sensitive tumors so it follows logically that these patients would benefit. Only long-term data from a well-designed trial that includes detailed tumor information will help us to understand whether we are helping patients or allowing more time for metastasis by changing our treatment algorithm.
There are limitations to the current study. First, because in NCDB data, it is not possible to ascertain exact chemotherapy regimens, we do not know exactly what the patients received.
Nevertheless, we applied careful, clinically reasoned assignment to treatment groups, according to criteria that distinguish patients most likely to have received systemic chemotherapy separate from radiation. Second, NCDB does not contain other endpoints such as local and distant recurrence rates which would be of interest. Third, because this was an observational study, there may be selection bias in the assignment of patients to IC vs standard chemoradiation that could affect the pathologic and oncologic outcome comparisons. However, recognizing that the most powerful predictor of use of IC was the institutional practice pattern, rather than patient characteristics, confounding by indication was likely less influential, as treatment decisions seem to have more to do with the provider than patient differences. Further, because the clinical and pathologic outcomes were nearly identical, even in this national data set, it is unlikely that clinically important confounding has altered the conclusions.
In conclusion, the use of IC for patients with locally advanced rectal cancer in NCDB is increasing over time, but it is still used in only a minority of patients in the US. Overall, the strongest predictor of treatment algorithm including IC was the treating institution's rate of use of IC, indicating that patients are receiving different treatments at different hospitals, driven primarily by local practice patterns. We found no association between the use of IC and improved overall survival or rate of pathologic complete response. Thus, prospective data are needed to better establish the role of IC in the management of locally advanced rectal cancer.
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